You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-DA-22-018: Advancing Validated Drug Targets for Substance Use Disorders (R41/R42- Clinical Trial Not Allowed)

    Release Date: 07-29-2021Open Date: 01-18-2022Due Date: 02-18-2022Close Date: 02-19-2022

    Background Substance use disorders (SUDs) affect people from all walks of life and all age groups. These illnesses are common, recurrent, and often serious, but they are treatable, and many people recover. SUDs occur when the recurrent use of drugs cause clinically significant impairment, including health problems, disability, and failure to meet major responsibilities at work, school, or home. T ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. RFA-DA-22-023: Advancing Validated Drug Targets for Substance Use Disorders (R43/R44- Clinical Trial Not Allowed)

    Release Date: 07-29-2021Open Date: 01-18-2022Due Date: 02-18-2022Close Date: 02-19-2022

    Background Substance use disorders (SUDs) affect people from all walks of life and all age groups. These illnesses are common, recurrent, and often serious, but they are treatable, and many people recover. SUDs occur when the recurrent use of drugs causes clinically significant impairment, including health problems, disability, and failure to meet major responsibilities at work, school, or home. ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. PAR-21-057: Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 11-19-2020Open Date: 01-22-2021 Due Dates: Multiple Close Date: 09-08-2023

    Background A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints, as well as composite biomarkers or biomarker signatures. Becaus ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. 8.3: Animal Production and Protection

    Release Date: 09-10-2021Open Date: 09-10-2021Due Date: 11-03-2021Close Date: 11-03-2021

    Protein and other nutrients from animal sources are an important component of diets worldwide. Agricultural animals also provide skins, fiber, feathers and other products with economic importance. There is a growing need for these products as the global population expands and demand becomes higher also due to more disposable income for hundreds of millions of people. Fulfilling this need will requ ...

    SBIRPhase IDepartment of AgricultureNational Institute of Food and Agriculture
  5. 8.7: Aquaculture

    Release Date: 09-10-2021Open Date: 09-10-2021Due Date: 11-03-2021Close Date: 11-03-2021

    The Aquaculture topic area funds research projects with the overall goal of leading to improved production efficiency and increased competitiveness of private sector, commercial aquaculture in the United States. This topic area aims to develop new technologies that will enhance the knowledge and technology base necessary for the expansion of the domestic aquaculture industry. Seafood production fr ...

    SBIRPhase IDepartment of AgricultureNational Institute of Food and Agriculture
  6. RFA-TR-21-010: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

    Release Date: 01-13-2021Open Date: 03-13-2021 Due Dates: Multiple Close Date: 01-13-2022

    A. Overview While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underly multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molecu ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. 8.8: Biofuels and Biobased Products

    Release Date: 09-10-2021Open Date: 09-10-2021Due Date: 11-03-2021Close Date: 11-03-2021

    The objective of this topic area is to promote the use of non-food biobased products and biofuels by developing new or improved technologies that will lead to increased competitiveness of value-added products from agricultural materials. This research will lead to new opportunities to diversify agriculture and enhance agriculture’s role as a reliable supplier of raw materials to industry. Histor ...

    SBIRPhase IDepartment of AgricultureNational Institute of Food and Agriculture
  8. PAR-21-282: Blueprint Medtech: Small Business Translator (U44- Clinical Trial Optional)

    Release Date: 08-20-2021Open Date: 09-20-2021 Due Dates: Multiple Close Date: 06-21-2024

    Blueprint MedTech The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). Innovators developing groundbreaking medical ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. PAR-21-233: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 04-23-2021Open Date: 07-10-2021 Due Dates: Multiple Close Date: 04-06-2024

    A. Overview Recent advances in biology offer unprecedented opportunities to discover new treatments for nervous system disorders. Biotherapeutic development, however, has inherent complexities with regards to characterization, manufacturing, delivery, and administration. Many academic laboratories and small business enterprises don’t have the full scope of expertise and resources available; thi ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. 8.4: Conservation of Natural Resources

    Release Date: 09-10-2021Open Date: 09-10-2021Due Date: 11-03-2021Close Date: 11-03-2021

    The goal of the program is to commercialize innovative technologies that are developed with the purpose to conserve, monitor, improve and/or protect the quality and/or quantity of natural resources and reduce potential waste streams while sustaining climate-smart, optimal farm and forest productivity and profitability. The objective of this topic area is the conservation of soil, water, air, and o ...

    SBIRPhase IDepartment of AgricultureNational Institute of Food and Agriculture
US Flag An Official Website of the United States Government